

Special Issue

Novel Therapeutic Targets in Melanoma

Message from the Guest Editors

Dear colleagues, Melanoma is the deadliest form of skin cancer. During the last ten years, melanoma has been a figurehead for targeted therapies and immunotherapy development. Currently, the 5-year overall survival rate for BRAF-mutated patients treated with first-line therapies targeting BRAFV600E and MEK is only around 30 percent, and for patients treated with immunotherapies, it is around 40 percent for anti-PD1 alone and 50 percent for anti-PD1 plus anti-CTLA4. Unfortunately, even if targeted therapies and immunotherapies have seen huge progress, we have now arrived at a plateau. In this Special Issue, we want to highlight different new potential strategies regarding the melanoma cells themselves and the tumor microenvironment to bypass resistance and smash this glass ceiling.

Guest Editors

Dr. Stephane Rocchi

INSERM U1065, Team 12, Centre Méditerranéen de Médecine Moléculaire, Université Côte d'Azur, Nice, France.

Dr. Michaël Cerezo

INSERM U1065, Team 12, Centre Méditerranéen de Médecine Moléculaire, Université Côte d'Azur, Nice, France.

Deadline for manuscript submissions

closed (31 January 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/66025

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)